The incidence of cough: A comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist

International Journal of Clinical Practice

Volumn 53, Issue 2, 1999, Pages 99-103

  Lacourciere, Yves ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; PLACEBO; TELMISARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; FEMALE; FREQUENCY ANALYSIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SELF EVALUATION; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; COUGH; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LISINOPRIL; MALE; MIDDLE AGED; PLACEBO EFFECT; RENIN-ANGIOTENSIN SYSTEM;

EID: 0032994748     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Gradman AH, Arcuri KE, Goldberg AI et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-1350.
2. Jackson EK, Garrison JC. Renin and angiotensin. In: Hardman JG, Limbird LE, Eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw-Hill, 1996; 733-758.
3. Burnier M, Waeber B, Brunner HR. The advantages of angiotensin II antagonism. J Hypertens 1994; 12(2): S7-S15.
4. Morice AH, Brown MJ, Higenbottam T. Cough associated with angiotensin converting enzyme inhibitors. J Cardiovasc Pharmacol 1989; 13(suppl 3): S59-S62.
5. Timmermans PBMWM, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45(2): 205-251.
6. Oliverio MI, Coffman TM. Angiotensin-II receptors: new targets for anti-hypertensive therapy. Clin Cardiol 1997; 20: 3-6.
7. van Meel JC, Redemann N, Haigh RM. Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically-instrumented transgenic rats. Arzneimittelforschung 1996; 46(8): 755-759.
8. Wienen W, Hauel N, van Meel JC et al. Pharmacological characterisation of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110(1): 245-252.
9. Lacourcière Y, Brunner H, Irwin R et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387-1393.
10. Benz J, Oshrain C, Henry D et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37(2): 101-107.
11. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy, and tolerability in the management of hypertension. Drugs 1996; 51(5): 820-845.
12. Jackson EA. Issues with antihypertensive therapy: safety perspectives. Drug Intell Clin Pharm 1988; 22: 115-124.